Lung Diseases

Boehringer Ingelheim has over 100 years of heritage in respiratory disease and we have emerged as a leader in the area of interstitial lung diseases (ILD). We have paved the way with a treatment to slow disease progression of idiopathic pulmonary fibrosis (IPF), a form of ILD that around 2,170 Australians are diagnosed with each year. Our aspiration is to further revolutionise the treatment landscape by developing therapies that seek to restore lung health and prevent pulmonary fibrosis. We’re continuing to seek scientific breakthroughs to address unmet medical needs in other chronic lung diseases including bronchiectasis.

_PC-AU-103887